In Vitro Effect of Soy Isoflavone and Equol on Soluble CD40L Release Stimulated by Ristocetin in Platelets from Postmenopause Women


The inhibition of specific flavonoid on the in vitro platelet aggregation induced by collagen, arachidonic acid and thromboxane A2 (TxA2) agonist, seems to be related mostly to their ability to compete for binding to the TxA2 receptor (TP). The aim of this study was to analyze the effect of soy isoflavone and equol in terms of inhibiting the platelet aggregation and sCD40L release stimulated by ristocetin, an in vitro-activator of glycoprotein Ib/IX/V, in platelets from postmenopausal women. When platelets were stimulated by 0.75 mg/ml ristocetin, equol (10 μM) exhibited a greater inhibitory activity on platelet aggregation (~68%) than genistein or daidzein. The effect of equol was dependent on the concentration of platelet aggregation agonist. In the presence of ristocetin (0.75 mg/ml, 1.125 mg/ml and 1.5 mg/ml), the inhibitory effect of 10 μM equol was 68% ± 5%, 54% ± 4% and 31% ± 5%, respectively. Equol (10 μM) was a potent inhibitor (~35%) of sCD40L release when stimulated with 1.5 mg/ml ristocetin. However, no significant differences were noted in platelets incubated in the presence of genistein or daidzein and stimulated by ristocetin. On the other hand, SQ29548, a high TP antagonist, also inhibited the sCD40L release stimulated by ristocetin. Finally, 10 μM of genistein, daidzein or equol did not significantly affect the thromboxane B2 production when platelets were incubated with 1.5 mg/ml ristocetin. The relevance of this study was to find that equol exhibits a potent activity by inhibiting ristocetin-induced sCD40L release, suggesting that soy isoflavone has important biological effects on the hemostatic system. However, clinical trials will be necessary to assess the effect of equol on platelet and their impact on inflammatory markers.

Share and Cite:

Gonzalez, N. , Garrido, A. , Acevedo, I. and Valladares, L. (2015) In Vitro Effect of Soy Isoflavone and Equol on Soluble CD40L Release Stimulated by Ristocetin in Platelets from Postmenopause Women. Journal of Biomedical Science and Engineering, 8, 24-30. doi: 10.4236/jbise.2015.81002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Setchell, K.D. and Cassidy, A. (1990) Dietary Isoflavones: Biological Effects and Relevance to Human Health. Journal of Nutrition, 129, 758S-767S.
[2] Jackson, R.L., Greiwe, J.S. and Schwen, R.J. (2011) Emerging Evidence of the Health Benefits of S-Equol, an Estrogen Receptor β Agonist. Nutrition Review, 69, 432-448.
[3] Cano, A., García-Pérez, M.A. and Tarín, J.J. (2010) Isoflavones and Cardiovascular Disease. Maturitas, 67, 219-226.
[4] Siow, R.C. and Mann, G.E. (2010) Dietary Isoflavones and Vascular Protection: Activation of Cellular Antioxidant Defenses by SERMs or Hormesis? Molecular Aspects of Medicine, 31, 468-477.
[5] Li, Z., Delaney, M.K., O’Brien, K.A. and Du, X. (2010) Signaling during Platelet Adhesion and Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 2341-2349.
[6] Gawaz, M., Langer, H. and May, A.E. (2005) Platelets in Inflammation and Atherogenesis. The Journal of Clinical Investigation, 115, 3378-3384.
[7] Nurden, A.T. (2011) Platelets, Inflammation and Tissue Regeneration. Thrombosis and Haemostasis, 105, S13-S33.
[8] Dong, J.F., Berndt, M.C., Schade, A., McIntire, L.V., Andrews, R.K. and López, J.A. (2001) Ristocetin-Dependent, but Not Botrocetin-Dependent, Binding of von Willebrand Factor to the Platelet Glycoprotein Ib-IX-V Complex Correlates with Shear-Dependent Interactions. Blood, 97,162-168.
[9] Enomoto, Y., Adachi, S., Matsushima-Nishiwaki, R., Doi, T., Niwa, M., Akamatsu, S., Tokuda, H., Ogura, S., Yoshimura, S., Iwama, T. and Kozawa, O. (2010) Thromboxane A2 Promotes Soluble CD40 Ligand Release from Human Platelets. Atherosclerosis, 209, 415-421.
[10] Munoz, Y., Garrido, A. and Valladares, L. (2009) Equol Is More Active than Soy Isoflavone Itself to Compete for Binding to Thromboxane A(2) Receptor in Human Platelets. Thrombosis Research, 123, 740-774.
[11] Guerrero, J.A., Lozano, M.L., Castillo, J., Benavente-Garcia, O., Vicente, V. and Rivera, J. (2005) Flavonoids Inhibit Platelet Function through Binding to the Thromboxane A2 Receptor. The Journal of Thrombosis and Haemostasis, 3, 369-376.
[12] Garrido, A., Munoz, Y., Sierralta, W. and Valladares, L. (2012) Metabolism of Dehydroepiandrosterone Sulfate and Estrone- Sulfate by Human Platelets. Physiological Research, 61, 381-388.
[13] Schonbeck, U. and Libby, P. (2001) The CD40/CD154 Receptor/Ligand Dyad. Cellular and Molecular Life Sciences, 58, 4-43.
[14] Lievens, D., Zernecke, A., Seijkens, T., Soehnlein, O., Beckers, L., Munnix, I.C., Wijnands, E., Goossens, P., van Kruchten, R., Thevissen, L., Boon, L., Flavell, R.A., Noelle, R.J., Gerdes, N., Biessen, E.A., Daemen, M.J., Heemskerk, J.W., Weber, C. and Lutgens, E. (2010) Platelet CD40L Mediates Thrombotic and Inflammatory Processes in Atherosclerosis. Blood, 116, 4317-4327.
[15] Derosa, G., D’Angelo, A., Mugellini, A., Pesce, R.M., Fogari, E. and Maffioli, P. (2012) Evaluation of Emerging Biomarkers in Cardiovascular Risk Stratification of Hypertensive Patients: A 2-Year Study. Current Medical Research and Opinion, 28, 1435-1445.
[16] Halushka, P.V., Mais, D.E., Mayeux, P.R. and Morinelli, T.A. (1989) Thromboxane, Prostaglandin and Leukotriene Receptors. Annual Review of Pharmacology and Toxicology, 29, 213-239.
[17] Giannarelli, C., Zafar, M.U. and Badimon, J.J. (2010) Prostanoid and TP-Receptors in Atherothrombosis: Is There a Role for Their Antagonism? Thrombosis and Haemostasis, 104, 949-954.
[18] Ostertag, L.M., O’Kennedy, N., Kroon, P.A., Duthie, G.G. and de Roos, B. (2010) Impact of Dietary Polyphenols on Human Platelet Function—A Critical Review of Controlled Dietary Intervention Studies. Molecular Nutrition & Food Research, 54, 60-81.
[19] Navarro-Núnez, L., Castillo, J., Lozano, M.L., Martínez, C., Benavente-García, O., Vicente, V. and Rivera, J. (2009) Thromboxane A2 Receptor Antagonism by Flavonoids: Structure-Activity Relationships. Journal of Agricultural and Food Chemistry, 57, 1589-1594.
[20] Sacks, F.M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P. and Winston, M. (2006) Soy Protein, Isoflavones, and Cardiovascular Health: A Summary of a Statement for Professionals from the American Heart Association Nutrition Committee. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1689-1692.
[21] Xiao, C.W. (2008) Health Effects of Soy Protein and Isoflavones in Humans. Journal of Nutrition, 138, 12445-12495.
[22] Zubik, L. and Meydani, M. (2003) Bioavailability of Soybean Isoflavones from Aglycone and Glucoside Forms in American Women. The American Journal of Clinical Nutrition, 77, 1459-1465.
[23] Bolca, S., Urpi-Sarda, M., Blondeel, P., Roche, N., Vanhaecke, L., Possemiers, S., Al-Maharik, N., Botting, N., De Keukeleire, D., Bracke, M., Heyerick, A., Manach, C. and Depypere, H. (2010) Disposition of Soy Isoflavones in Normal Human Breast Tissue. The American Journal of Clinical Nutrition, 91, 976-984.
[24] Larkin, T., Price, W.E. and Astheimer, L. (2008) The Key Importance of Soy Isoflavone Bioavailability to Understanding Health Benefits. Critical Reviews in Food Science and Nutrition, 48, 538-552.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.